TABLE 4.

Anti‐angiogenic drugs that approved by the China NMPA, US FDA, and EMA

Drug	The China NMPA‐approved indication	The US FDA‐approved indication	The EMA‐approved indication
Bevacizumab	Plus platinum‐based chemotherapy for treatment‐naïve, unresectable, metastatic/relapsed, non‐squamous NSCLC.	Plus platinum‐based chemotherapy for treatment‐naïve, unresectable, metastatic/relapsed, non‐squamous NSCLC.	Plus platinum‐based chemotherapy for treatment‐naïve, unresectable, metastatic/relapsed, non‐squamous NSCLC.
#QL1101	Plus platinum‐based chemotherapy for treatment‐naïve, unresectable, metastatic/relapsed, non‐squamous NSCLC.	/	/
#Anlotinib	Third‐line therapy for advanced NSCLC.	/	/

Abbreviations: EMA, European Medicines Agency; FDA, Food and Drug Administration; NMPA, National Medical Products Administration; NSCLC, non‐small cell lung cancer; #, domestic drug.